ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,870.62
-1.32%
US Tech 100
19,880.00
-2.30%
Dow Jones
43,444.99
-0.70%
Brent Oil
71.25
0.50%
Bitcoin
91,295.02
0.26%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Viridian Therapeutics Inc (VRDN) Quote

Viridian Therapeutics Inc

Viridian Therapeutics Inc (VRDN)

Viridian Metals Inc
20.14
-1.50
(-6.93%)
Closed November 16 4:00PM
Delayed by 15 minutes
19.00
-1.14
(-5.66%)
After Hours: 7:59PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
20.14
Bid
19.01
Ask
21.00
Volume
1,833,127
19.65 Day's Range 21.77
11.40 52 Week Range 27.20
Market Cap
1.287B
Previous Close
21.64
Open
21.72
Last Trade
41
@
21
Last Trade Time
Financial Volume
$ 37,505,062
VWAP
20.4596
Average Volume (3m)
1,513,895
Shares Outstanding
63,889,920
Dividend Yield
-
PE Ratio
-5.41
Earnings Per Share (EPS)
-3.72
Revenue
314k
Net Profit
-237.73M

About Viridian Therapeutics Inc

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.viridiantherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Viridian Therapeutics Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker VRDN. The last closing price for Viridian Therapeutics was $21.64. Over the last year, Viridian Therapeutics shares have traded in a share price range of $ 11.40 to $ 27.20.

Viridian Therapeutics currently has 63,889,920 shares outstanding. The market capitalization of Viridian Therapeutics is $1.38 billion. Viridian Therapeutics has a price to earnings ratio (PE ratio) of -5.41.

Ask ADVFN Intelligence (AI)

VRDN Latest News

More News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in...

November 12 2024
Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

November 05 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

September 30 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 30 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.525-18.34583417824.66527.218.99177098923.09633888CS
4-4.1-16.914191419124.2427.218.99101262323.31449271CS
124.629.60102960115.5427.213.2151389520.71959744CS
265.0233.201058201115.1227.211.4123968717.71797128CS
525.1434.26666666671527.211.4107923417.92511135CS
1560.874.5147898287519.27399.4770635619.82027566CS
260-1.25-5.8438522674121.39399.4757486719.63474546CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 0.2853
(52.40%)
1.17B
CYCNCyclerion Therapeutics Inc
$ 2.5306
(42.97%)
11.99M
SPPLSIMPPLE Ltd
$ 1.2503
(41.60%)
165.69M
PULMPulmatrix Inc
$ 6.5586
(39.54%)
5.37M
ZTEKZentek Ltd
$ 1.2574
(29.96%)
309.67k
TFFPTFF Pharmaceuticals Inc
$ 0.376101
(-76.49%)
9.35M
EYENEyenovia Inc
$ 0.10185
(-70.05%)
52.8M
CTXRCitius Pharmaceuticals Inc
$ 0.1974
(-39.89%)
11.26M
VVPRVivoPower International PLC
$ 0.8151
(-39.62%)
2.34M
IPWiPower Inc
$ 0.7302
(-39.15%)
1.15M
CEROCERo Therapeutics Holdings Inc
$ 0.2853
(52.40%)
1.17B
ELABElevai Labs Inc
$ 0.0211
(-19.47%)
380.03M
NVDANVIDIA Corporation
$ 141.98
(-3.26%)
253.02M
SPPLSIMPPLE Ltd
$ 1.2503
(41.60%)
165.69M
STISolidion Technology Inc
$ 0.44
(25.71%)
140.02M

VRDN Discussion

View Posts
Monksdream Monksdream 2 months ago
VRDN more upside possible

👍️0
it_happens it_happens 2 months ago
Touched 20s today. Maybe it will stay above 20 tomorrow
👍️0
power11 power11 2 months ago
LOW 20'S BY WEEKEND IMO !!!
GOOD LUCK
👍️0
it_happens it_happens 2 months ago
Good news. I don't think that this is merely a one-day runner.
👍️0
power11 power11 2 months ago
BTIG RESEARCH ADJUST PRICE TARGET TO 56 FROM 46; STRONG BUY !!
👍️0
it_happens it_happens 2 months ago
Over 15 and having a good day today
👍️0
Monksdream Monksdream 2 months ago
VRDN under $15
👍️0
Apprentice Apprentice 3 years ago
I put into it a lot of $
423 shares!
👍️0
Apprentice Apprentice 3 years ago
It just doesn't want to move above $18
Yet, it's not diving much either.
What do you think at this point? Sell temporarily and by later low?
My average is too high @17.76 !
👍️0
crudeoil24 crudeoil24 3 years ago
Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.
👍️0

Your Recent History

NASDAQ
VRDN
Viridian Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved